Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Breast cancer is the most frequently diagnosed cancer and the principal cause of mortality
by malignancy in women and represents a main problem for public health worldwide. Tumor …

Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …

Background Aromatase inhibitors are a standard of care for hormone receptor-positive
locally advanced or metastatic breast cancer. We investigated whether the selective …

These NCCN Guidelines Insights highlight the important updates/changes to the surgical
axillary staging, radiation therapy, and systemic therapy recommendations for hormone …

Background Resistance to endocrine therapy in breast cancer is associated with activation
of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early …

Purpose: We undertook this study to determine the prevalence of estrogen receptor (ER) α
(ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to …

Purpose Cross-talk between signal transduction pathways likely contributes to hormone
resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian …

Summary Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was
designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg) …

Purpose To develop recommendations about endocrine therapy for women with hormone
receptor (HR)–positive metastatic breast cancer (MBC). Methods The American Society of …